News & Updates

A new genomic predictive model has identified mutated genes that are associated with the most aggressive anaplastic thyroid cancer (ATC), according to a study.

Ultraprocessed foods (UPFs) are associated with several preventable diseases and must be viewed not only through a nutritional lens but also as addictive, industrially engineered substances, which can be likened to cigarettes, suggests a recent study.

Treatment with the combination of savolitinib plus osimertinib prolongs progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC) harbouring EGFR mutation and MET amplification, as shown in the phase III SACHI trial.

Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to confer greater protection against the development of colorectal cancer (CRC) as compared with aspirin, according to a retrospective study.

Treatment with zanidatamab combined with tislelizumab and/or chemotherapy (CT) significantly improves progression-free survival (PFS) in patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA), as shown in the primary analysis from HERIZON-GEA-01.

In the treatment of patients with relapsed or refractory follicular lymphoma, adding tafasitamab to lenalidomide and rituximab appears to improve progression-free survival (PFS) while having an acceptable safety profile, according to the phase III inMIND study.

Combining S-1 and oxaliplatin (SOX) as an adjuvant chemotherapy significantly improves overall survival (OS) and disease-free survival (DFS) compared with S-1 alone in patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma, according to the final results of the CAPITAL trial presented at ASCO GI 2026.

Dual anti-HER2 blockade with a chemotherapy-free backbone of palbociclib plus letrozole may serve as an alternative treatment to patients with HR-positive/HER2-positive early breast cancer, suggests the phase II TOUCH study, noting similar rates of pathological complete response (pCR) to that of paclitaxel.